



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/924,400	08/07/2001	Tony N. Frudakis	210121.419C12	7385

500 7590 01/19/2006

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE
SUITE 6300
SEATTLE, WA 98104-7092

EXAMINER

ZEMAN, MARY K

ART UNIT PAPER NUMBER

1631

DATE MAILED: 01/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary	Application No.	Applicant(s)	
	09/924,400	FRUDAKIS ET AL.	
	Examiner	Art Unit	
	Mary K. Zeman	1631	

All participants (applicant, applicant's representative, PTO personnel):

(1) Mary K. Zeman (USPTO). (3)_____.

(2) Julie Urvater (Appl Rep). (4)_____.

Date of Interview: 13 January 2006.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: 15 and 18.

Identification of prior art discussed: Frudakis 98/45328.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: see attached.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

See Attached

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Art Unit: 1631

Interview Summary, Attachment:

1/13/06

Issues regarding the rejections of record in this application were discussed. Potential claim language amendments to obviate the enablement rejection were discussed. Possible amendments to overcome the art and indefiniteness rejections were also discussed. Applicant was advised that amendments cannot introduce new matter. The examiner probed the file for the alignment of the claimed sequences with the applied prior art. In the IFW record, 11/8/02, in the Examiner Search Notes, the Examiner identified the original alignments relied upon. WO 98/45328 Frudakis et al, AAV68996, #188 shows approximately 300 contiguous nucleotides in common with SEQ ID NO: 302. In reviewing this file, the next sequence alignment was discovered: WO 98/45328 also discloses AAV68995, #187, which has approximately 650+ contiguous nucleotides in common with SEQ ID NO: 303.

Illustrative of the issues which may be applied again in the future with the oligonucleotide claim and the stretches of polyA in both sequences are the alignments of SEQ ID NO: 303 with AQ204617, AA533501, AQ063365, AI344928 and AI 344936. Each of these disclose short stretches of contiguous sequence in common with SEQ ID NO: 303.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (571) 272 0723

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, PhD can be reached on (571) 272 0718. The fax phone number for the organization where this application or proceeding is assigned is 571 273 8300.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of

Art Unit: 1631

the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.


MARY K. ZEMAN
PRIMARY EXAMINER
APR 16 31
1/13/06

8996 standard; DNA; 1853 BP.

Claim 1, Page 138-139, 173pp; English.

AAV68800 to AAV68998 represent nucleotide sequences which encode human breast tumour specific polypeptides. Detection or measurement of human breast tumour specific polypeptides and nucleotide sequences, or the corresponding RNA in a sample, is used for diagnosis and monitoring of breast cancer. Human breast tumour specific polypeptides and nucleotide sequences, and the vectors containing the DNAs, are also useful in vaccines for inhibiting development (for prevention or therapy) of breast cancer. The polypeptides may also be used to raise monoclonal antibodies, used as immunoassay reagents.

Sequence 1853 BP; 521 A; 381 C; 492 G; 431 T; 28 other:

Query Match 12.4%; Score 252; DB 19; Length 1853;
Best Local Similarity 99.7%; Pred. No. 8,9e-86;
Matches 302; Conservative 0; Mismatches 1; Indels 0; Gaps 0

34 TCTTGTGGAAGAACCATTTGGTCTCAGAGCAGATGGCAGTGGTGGCCGTTC 93
256 TCTTGTGGAAGAACCATTTGGTCTCAGAGCAGATGGCAGTGGTGGCCGTTC 315
94 TTCCCTGTGAGAGGAGGAGGAGGAGCAGACAGTGGGCACTTGTGAGAGCAGAC 153
316 TTCCCTGTGAGAGGAGGAGGAGGAGCAGACAGTGGGCACTTGTGAGAGCAGAC 375
154 TGTGCTATGAGACACTCAGAGCAGAGATGGCAGATGGTGGCCGACATGCTTCC 213
376 TGTGCTATGAGAGACTCAGAGCAGAGATGGGCAAGTGGTGGCCGACATGCTTCC 435
214 TGCAGGGGAGTGGCAGAGCAGACAGTGGGCGCTTCTGAGAGCAGAGCAGTGTG 273
436 TGCAGGGGAGTGGCAGAGCAGACAGTGGGCGCTTCTGAGAGCAGAGCAGTGTG 495
274 AAGCACTCAGAGAGAGAGTGGCAGAGTGGTGGTGGTGGTGGTGGTGGTGGTGG 333
496 AAGCACTCAGAGAGAGAGTGGCAGAGTGGTGGTGGTGGTGGTGGTGGTGGTGG 555
334 AGC 336
556 AGC 558

RESULT 41
AACB1007
ID AACB1007 standard; cDNA; 1853 BP.
AACB1007:
13-FEB-2001 (first entry)
Human B1Agl antigen protein coding exon cDNA SEQ ID NO: 295.
Human B1Agl antigen protein coding exon cDNA SEQ ID NO: 295.
Human breast tumour-specific antigen: cytosolic; vaccine:
breast cancer; B1Agl; B1Agl; B1Agl; ss.
Homo sapiens
MO200061753-A2.
19-OCT-2000.
07-APR-2000; 2000MO-US09312.
09-APR-1999; 99US-0289198.
28-OCT-1999; 99US-0429755.
23-MAR-2000; 2000US-0534825.
(CORI-) CORIXA CORP.
Frudakis TM, Smith JM, Reed SG, Misher LE, Retter AN, Dillon DC;

Claim 1; Page 138-139; 173pp; English.

AAV68800 to AAV68998 represent nucleotide sequences which encode human breast tumour specific polypeptides. Detection or measurement of human breast tumour specific polypeptides and nucleotide sequences, or the corresponding RNA in a sample, is used for diagnosis and monitoring of breast cancer. Human breast tumour specific polypeptides and nucleotide sequences, and the vectors containing the DNAs, are also useful in vaccines for inhibiting development (for prevention or therapy) of breast cancer. The polypeptides may also be used to raise monoclonal antibodies, used as immunoassay reagents.

Sequence 1853 BP; 521 A; 381 C; 492 G; 431 T; 28 other:

Query Match 12.4%; Score 252; DB 19; Length 1853;
Best Local Similarity 99.7%; Pred. No. 8,9e-86;
Matches 302; Conservative 0; Mismatches 1; Indels 0; Gaps 0

OY 34 TCCTGTGTAAGAACCATTTGGTCTCAGAGCAAGATGGCGATGGTGCCCTTGC 93
DB 256 TCCTGTGTAAGAACCATTTGGTCTCAGAGCAAGATGGCGATGGTGCCCTTGC 315
OY 94 TTCCTGTGTCAGAGGAGCGGCCAAGACACGCGGCCACTTCTGGAGCACAGAC 153
DB 316 TTCCCCTGTCTCAGAGGAGAGCGGCCAAGACACGCGGCCACTTCTGGAGCACAGAC 375
OY 154 TCTGCTATGAAGACACTCAGAGCAAGATGGCGAAGTGCGCGCCACTGCTCCCTGC 213
DB 376 TCTGCTATGAAGACACTCAGAGCAAGATGGCGAAGTGCGCGCCACTGCTCCCTGC 435
OY 214 TGCGAGGAGGAGTGCGCAAGACACGTCGGCGCTTCTGGAGCACAGACGACTGCTATG 273
DB 436 TGCGAGGAGGAGTGCGCAAGACACGTCGGCGCTTCTGGAGCACAGACGACTGCTATG 495
OY 274 AAGCACTCAGAGCAAGATGGCGCAAGTGCTCTCCACTGCTTCCCTGTCAGAGGG 333
DB 496 AAGCACTCAGAGCAAGATGGCGCAAGTGCTCTCCACTGCTTCCCTGTCAGAGGG 555
OY 334 AGC 336
DB 556 AGC 558

RESULT 41
AACB1007
ID AACB1007 standard; cDNA: 1853 BP.
AACB1007:
XX AACB1007:
XX 13-FEB-2001 (first entry)
DE Human B11Ag1 antigen protein coding exon cDNA SEQ ID NO: 295.
DT Human B11Ag1 antigen protein coding exon cDNA SEQ ID NO: 295.
XX Human breast tumour-specific antigen: cytosolic; vaccine:
KW breast cancer; B11Ag1; B11Ag1; B11Ag1; ss.
XX Homo sapiens
OS Homo sapiens
PN WO200061753-A2.
XX 19-OCT-2000.
PD 07-APR-2000; 2000WO-US09312.
PF 09-APR-1999; 99US-0289198.
PR 28-OCT-1999; 99US-0429755.
PR 23-MAR-2000; 2000US-0534825.
XX (CORI-) CORIXA CORP.
XX Frudakis TM, Smith JM, Reed SG, Wisher LE, Retter AN, Dillon DC;

OS Homo sapiens.
 PN W0200130152-A2.
 PD 29-NOV-2001.
 PF 22-MAY-2001, 2001MO-US16776.
 XX
 XX 24-MAY-2000: 2000US-0537505.
 PR 08-JUN-2000: 2000US-0539583.
 PR 26-OCT-2000: 2000US-0699295.
 PR 16-MAR-2001: 2001US-0810936.
 XX
 PA (CORI-) CORIXA CORP
 PI Fradette TM, Reed SC, Smith JM, Misher LE, Dillon DC, Retter MW;
 PI Wang A, Shelly YAM, Harlocker SL, Day CH;
 XX WPI: 2002-089919/12.
 DR P-PSDB: AAU74390.
 XX
 PT New breast tumour proteins and polynucleotides encoding them, useful for
 PT treating and/or preventing cancer, particularly breast cancer, and for
 PT eliciting humoral and/or cellular immune response
 XX
 PS Claim 1: Page 239; 245pp: English.
 XX
 CC The invention relates to novel breast tumour polynucleotides and
 CC polypeptides. The polypeptides and polynucleotides are useful in
 CC pharmaceutical compositions for treating and/or preventing cancer,
 CC particularly breast cancer, and for eliciting an immune response.
 CC The polynucleotides may be used as probes or primers for nucleic acid hybridisation, in the
 CC design and preparation of ribozyme molecules for inhibiting expression of
 CC tumour polypeptides and proteins, and in recombinant DNA molecules to
 CC direct expression of a polypeptide in host cells. AAS9570-AAS9888
 CC represent novel human breast cancer protein coding sequences and
 CC PCR primers of the invention.
 XX
 SO Sequence 1155 BP: 346 A; 253 C; 296 G; 260 T; 0 other:
 Query Match 47.8%; Score 975; DB 24; Length 1155;
 Best Local Similarity 99.7%; Pred. No. 0;
 Matches 1155; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 ATGCTGTTGAGGTTGATTCATGCGCGCTGCTCTCTGTAAGAACCAATTGGTCTC 60
 DB 1 ATGCTGTTGAGGTTGATTCATGCGCGCTGCTCTCTCTGTAAGAACCAATTGGTCTC 60
 QY 61 AGGAGCAAGATGGGCAAGTGGTCCGCTTCCCTGCTGAGGAGAGCGCGAAG 120
 DB 61 AGGAGCAAGATGGGCAAGTGGTCCGCTTCCCTGCTGAGGAGAGCGCGAAG 120
 QY 121 AGCAAGCTGGGCACTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 180
 DB 121 AGCAAGCTGGGCACTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 180
 QY 181 ATGGGCAAGTGGTGGGCACTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 240
 DB 181 ATGGGCAAGTGGTGGGCACTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 240
 QY 241 GGGCTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 300
 DB 241 GGGCTTCTGAGAGCAGACGACTCTGCTATGAAAGACACTGAGAGCAG 300
 QY 301 TGGTGTGCGCACTCTTCCCTGCTGAGAGGAGAGCGGCAAGAGCAAGTGGGCGCTTGG 360
 DB 301 TGGTGTGCGCACTCTTCCCTGCTGAGAGGAGAGCGGCAAGAGCAAGTGGGCGCTTGG 360
 QY 361 GGAGACTAGCATGACAGTGGCTTCTGAGAGGAGAGCAAGTGGGCGCTTGG 420
 DB 361 GGAGACTAGCATGACAGTGGCTTCTGAGAGGAGAGCAAGTGGGCGCTTGG 420

QY 421 GACAAGCTCCACAGAGCTGCTGCTGGGTTAAAGTCCCAAGAAAGATCTCAGTCTATG 480
 DB 421 GACAAGCTCCACAGAGCTGCTGCTGGGTTAAAGTCCCAAGAAAGATCTCAGTCTATG 480
 QY 481 CTCAGGAGACTGAGCTGAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 540
 DB 481 CTCAGGAGACTGAGCTGAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 540
 QY 541 TCTGCAATGGGAATTCAGAAAGTAAAGTCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAG 600
 DB 541 TCTGCAATGGGAATTCAGAAAGTAAAGTCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAG 600
 QY 601 GTCTTGAACAAAG 660
 DB 601 GTCTTGAACAAAG 660
 QY 661 TGTGCTTAATGTTGCTGAG 720
 DB 661 TGTGCTTAATGTTGCTGAG 720
 QY 721 ACCACTTGCACAG 780
 DB 721 ACCACTTGCACAG 780
 QY 781 TATGCTGCTAATGAG 840
 DB 781 TATGCTGCTAATGAG 840
 QY 841 CATGAGCAAG 900
 DB 841 CATGAGCAAG 900
 QY 901 CTGGATGATATGAG 960
 DB 901 CTGGATGATATGAG 960
 QY 961 GTGACCTTCTGAG 1020
 DB 961 GTGACCTTCTGAG 1020
 QY 1021 GCCAGAGATATGCTGTTCTGAG 1080
 DB 1021 GCCAGAGATATGCTGTTCTGAG 1080
 QY 1081 AAG 1128
 DB 1081 AAG 1128
 RESULT 30
 AAV68995
 ID AAV68995 standard; DNA: 1512 BP.
 XX
 AC AAV68995:
 XX
 DT 22-JAN-1999 (first entry)
 XX
 DE DNA molecule encoding a breast tumour specific polypeptide #187.
 XX
 KW Human: breast cancer; breast tumour tissue; diagnosis; treatment;
 KW vaccine; epitope; endogenous; retroviral element; 88.
 OS Homo sapiens.
 PN W09845328-A2.
 PD 15-OCT-1998.
 PF 09-APR-1998: 98MO-US06939.
 PR 11-DEC-1997: 97US-0991789.
 PR 09-APR-1997: 97US-0838762.
 XX

INT SUMMARY

PA (CORI-) CORIXA CORP.

XX Frudakis TN, Reed SG, Smith JM;

XX WPI: 1998-557473/47.

XX New DNA sequences isolated from endogenous human retroviral element
PT - and related vectors, transformed cells, proteins and antibodies,
PT useful for diagnosis, treatment and prevention of breast cancer.

PS Claim 1: Page 137-138; 173pp; English.

XX AAV68800 to AAV68998 represent nucleotide sequences which encode human
CC breast tumour specific polypeptides. Detection or measurement of
CC human breast tumour specific polypeptides and nucleotide sequences,
CC or the corresponding RNA in a sample, is used for diagnosis and
CC monitoring of breast cancer. Human breast tumour specific polypeptides
CC and nucleotide sequences, and the vectors containing the DNAs, are also
CC useful in vaccines for inhibiting development (for prevention or
CC therapy) of breast cancer. The polypeptides may also be used to
CC raise monoclonal antibodies, used as immunoassay reagents.

XX Sequence 1512 BP; 406 A; 301 C; 393 G; 399 T; 13 other:

Query Match 24.1%: Score 491; DB 19; Length 1512;

Best Local Similarity 99.4%: Pred. No. 6.4e-180;

Matches 691; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

DB 916 CCAAAATATTCAGATGATGAAATACCACTCT 950

RESULT 31

XX AAC81006

XX AAC81006 standard; cDNA; 1512 BP.

XX AAC81006;

XX 13-FEB-2001 (first entry)

XX Human B11a1 antigen protein coding exon cDNA SEQ ID NO: 294.

XX Human: breast tumour-specific antigen; cytostatic; vaccine;

XX breast cancer: B18a1; B11a1; B15a1; ss.

XX Homo sapiens.

XX WO20061753-A2.

XX 19-OCT-2000.

XX 07-APR-2000; 2000WO-US09312.

XX 09-APR-1999; 98US-0289198.

XX 28-OCT-1999; 98US-0429755.

XX 23-MAR-2000; 2000US-0534825.

XX (CORI-) CORIXA CORP.

XX Frudakis TN, Smith JM, Reed SG, Misher LE, Retter MW, Dillon DC;

XX WPI: 2000-628403/60.

XX An isolated polypeptide comprising an immunogenic portion of a breast
PT tumor protein used for inhibiting the development of cancer, especially
PT breast cancer, and monitoring cancer progression in a patient.

XX Claim 4: Page 172; 187pp; English.

XX The present sequence is given in a specification relating to compositions
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide
CC sequences that are preferentially expressed in breast tumour tissue, and
CC the polypeptides encoded by such nucleotide sequences, are used in
CC compositions and vaccines to inhibit the development of cancer,
CC especially breast cancer. The progression of a cancer may be monitored by
CC carrying out detection of tumour-specific antigens at subsequent time
CC points and comparing the results from the different time points.
CC CD4+ and/or CD8+ T-cells isolated from the cancer patient may be treated
CC with tumour-specific polypeptides, polynucleotides encoding the
CC polypeptides or antigen presenting cells expressing the polypeptides. The
CC cells are then administered to the patient to inhibit development of
CC cancer.

XX Sequence 1512 BP; 406 A; 301 C; 393 G; 399 T; 13 other:

Query Match 24.1%: Score 491; DB 21; Length 1512;

Best Local Similarity 99.4%: Pred. No. 6.4e-180;

Matches 691; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

XX 34 TCTCTGTGAAGAACCAATTGCTCTCAGAGCAAGATGGGCAAGTGTGCTGCCGTTGC 93
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DB 256 TCTCTGTGAAGAACCAATTGCTCTCAGAGCAAGATGGGCAAGTGTGCTGCCGTTGC 315
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DB 316 TTCCCTGTGAGGAGAGGAGGCAAGAGCAAGTGGGCACTTCTGGAACCAACAGAC 375
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XX 154 TCTGTATGAAGACACTCAGAGCAAGATGGGCAAGTGTGCTGCCGTTGCCGTTGC 213
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
XX ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DB 376 TCTGTATGAAGACACTCAGAGCAAGATGGGCAAGTGTGCTGCCGTTGCCGTTGC 435

(3) INT. SUMMARY

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OK nucleic - nucleic search, using SW model

Run on: November 8, 2002, 08:45:54 : Search time 2565.15 Seconds

(without alignments)
12879.875 Million cell updates/sec

Title: US-09-924-400-303

Perfect score: 2040
Sequence: 1 atggtgctgagtgatc.....aaaaaaaaaaaaaaaa 2040

Scoring table: OLIGO NUC
Gapop 60.0 , Gapext 60.0

Searched: 16154066 seqs, 8097743376 residues

Word size : 15

Total number of hits satisfying chosen parameters: 1430706

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :
EST:
1: em_estba:
2: em_esthum:
3: em_estlin:
4: em_estmuc:
5: em_estov:
6: em_estpl:
7: em_estro:
8: em_estc:
9: gb_estc:
10: gb_estl:
11: gb_estl:
12: gb_estl:
13: gb_estl:
14: gb_estl:
15: em_estfun:
16: em_estom:
17: gb_gss:
18: em_gss_hum:
19: em_gss_inv:
20: em_gss_pln:
21: em_gss_vrt:
22: em_gss_fun:
23: em_gss_mam:
24: em_gss_mug:
25: em_gss_other:
26: em_gss_pro:
27: em_gss_rtd:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	ID	Description
1	184	9 0	521 17	AQ204617 HS-3229-B
2	141	6 9	865 12	BF676987 602084215
3	140	6 9	451 9	A1804733 cu42b03.x
4	137	6 7	289 9	AA533501 n196a04.s
5	129	6 3	531 17	AQ615477 HS-5144-B
6	117	5 7	621 14	BM763942 K-EST0045

7	117	5 7	633 14	BM763453 K-EST0044
8	117	5 7	817 14	BQ441373 ACBNCOURT
9	89	4 4	400 17	AQ124119 HS-3122-A
10	87	4 3	399 17	AQ030111 RPI111-39
11	87	4 3	544 9	AL703938 DXP2P686E
12	79	3 9	279 13	B1461255 603206584
13	73	3 6	385 17	AQ063365 CIT-HSP-2
14	59	2 9	707 17	AQ045796 Pan tCt01
15	57	2 8	607 17	B48260 RPI111-6K4
16	52	2 5	380 12	BF329652 RCB-BM027
17	50	2 5	592 17	AQ372700 RPI111-14
18	49	2 4	495 17	AQ469831 CITBI-EI-
19	49	2 4	557 17	AQ469663 CITBI-EI-
20	49	2 4	667 17	AG156382 Pan tCt01
21	49	2 4	697 17	AQ030113 RPI111-39
22	47	2 3	187 10	BE069869 CNI-BT039
23	47	2 3	476 17	AQ392059 CITBI-EI-
24	46	2 3	400 17	AQ057106 CIT-HSP-2
25	45	2 2	894 12	BF675049 602136643
26	44	2 2	460 17	AQ360298 HS-5035-A
27	41	2 0	710 17	AG165908 Pan tCt01
28	40	2 0	503 17	B55862 CIT-HSP-200
29	39	1 9	1011 17	AQ090910 HS-2055-B
30	38	1 9	458 17	AQ247090 HS-2055-B
31	37	1 8	424 17	AQ763344 HS-3162-A
32	37	1 8	694 12	BF720647 602693528
33	36	1 8	652 17	AG054405 Pan tCt01
34	35	1 7	156 9	A1349163 t07306.x
35	35	1 7	157 9	A1251211 qv38h06.x
36	35	1 7	160 9	A1305627 qv72f03.x
37	35	1 7	166 9	A1343314 t093912.x
38	35	1 7	184 10	AW302924 xrb6907.x
39	35	1 7	199 10	AW302925 xrb6908.x
40	35	1 7	224 9	A1344928 t094d12.x
41	35	1 7	232 9	A1335592 t094d12.x
42	35	1 7	239 9	A1344933 t094d12.x
43	35	1 7	239 9	A1344936 t094d12.x
44	35	1 7	250 9	A1335449 t094d12.x
45	35	1 7	360 9	A1494279 qv98c11.x

ALIGNMENTS

RESULT 1
LOCUS AQ204617 521 bp DNA linear GSS 17-SEP-1998
DEFINITION HS-3229-B1-G12-T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3229 Col=23 Row=N, DNA sequence.

ACCESSION AQ204617
VERSION AQ204617.1 GI:3615187
KEYWORDS GSS.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryote: Metazoa: Chordata: Vertebrata: Euteleostomi: Mammalia: Eutheria: Primates: Catarrhini: Hominoidea: Homo.
AUTHORS Mahalir, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T., Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and Hood, L.

TITLE Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
COMMENT High Throughput Sequencing Center
Contact: Mahalir, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T., Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and Hood, L.
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 3229 row: N column: 23

④ Int Summary

BASE COUNT	128 a	79 c	91 g	153 t
ORIGIN				

ORIGIN

Query Match	6.98;	Score 140;	DB 9;	Length 451;
Best Local Similarity	100.00;	Pred. No.	6.2e-25;	

916 AGGACTGCTCTCATACTTGGCTGATGTTGGATCAGCAAGTATAGTCAGCCTTCTACTT 975

Db 47 AGGACTGCTCTCATCTTGGTGTGATGTTGGATCAGCAAGTATAGTCAGCCTTCTACTT 106

976 GAGCAAAATATGTGATGTATCTTCTCAAGATCTATCTGGACAGACGGCCAGAGATATGCT 10335

Db 107 GAGCAATATGTGATCTTCTCAAGATCTATCTGGACAGACGGCCAGAGATATGCT 166

1036 GTTCTAGTCATCATGT 1055

Db- 167 GTTCTAGTCATCATGT 186

RESULT 4
AA533501

LOCUS	289 bp	mRNA	linear	EST
AAS33501				21-AUG-1997
nj96604.g1				
NCI_CGAP_Pr11				
Homo sapiens				
CDNA clone				
IMAGE:1000302,				

ACCESSION	AA533501
VERSION	AA533501 1 CT.2277507

KEYWORDS	EST.
SOURCE	human.

ORGANISM HOMO SAPIENS
Eukaryota; Metazoa; Ch

REFERENCE 1 (bases 1 to 289)

TITLE National Cancer Instit

JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strauss

Email: cgapbs-remail.n
Telefon Procurement: M1

Chuaqui, M.D., Michael
cDNA Library Preparation

CDNA Library Arrayed
DNA Sequencing by: Wa

LOCUS	AG045796	c	707 bp	DNA	linear	GSS 02-NOV-2001
DEFINITION	Pan troglodytes DNA, clone: PTB-024N04.R, genomic survey sequence.					
ACCESSION	AG045796					
VERSION	AG045796.1 GI:16582688					
SOURCE	GSS.					
ORGANISM	Pan troglodytes male lymphoblast DNA, clone_11b:PTB chimpanzee male BAC library clone:PTB-024N04.R.					
REFERENCE	Pan troglodytes					
AUTHORS	Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Eukaryota; Metazoa; Primates; Catarrhini; Homnidae; Pan.					
TITLE	Fujiyama, A., Hattori, M., Toyoda, A., Taylor, T.D., Yada, T., Tachik, Y., Watanabe, H. and Sakaki, Y.					
JOURNAL	BAC end sequences of library PTB					
REFERENCE	2 (Nases 1 to 707)					
AUTHORS	Fujiyama, A., Hattori, M., Toyoda, A., Taylor, T.D., Yada, T., Tachik, Y., Watanabe, H. and Sakaki, Y.					
TITLE	Direct Submission					
JOURNAL	Submitted (02-APR-2001) Aaso Fujiyama, The Institute of Physical and Chemical Research (RIKEN), Genomic Sciences Center (GSC), 1-7-2 Suhei-cho, Tsukuba, Ibaraki, Japan, 305-8565, Japan (E-mail: chimpesgsc@riken.go.jp, URL: http://hgp.gsc.riken.go.jp/, Tel:81-45-508-9111, Fax:81-45-503-9170)PTB This BAC end clones are derived from the chimpanzee BAC library PTB This BAC end was generated during the Rdb process and may have higher chance of clone tracking errors.					
COMMENT	PRIMERS					
FEATURES	Sequencing: M13Rev					
source	LIBRARY					
	Vector : pRS145					
	R.Site 1 : SacI					
	R.Site 2 : SacI.					
	Location/Qualifiers					
	1..707					
	/organism="Pan troglodytes"					
	/db_xref="taxon:9594"					
	/clone="PTB-024N04.R"					
	/sex="male"					
	/cell_type="Lymphoblast"					
	/clone_11b="PTB Chimpanzee Male BAC Library"					
BASE COUNT	233 a 145 c 85 g 217 t 7 others					
ORIGIN						
Query Match	2.98; Score 59; Ds 17; Length 707;					
Best Local Similarity	100.0%; Pctd. No. 1; De-05;					
Matches	59; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	1956 GGAAGAAATTCAGCTCTAAGACTGGAGCTTACACATCAATCAATCAGCAGCTAA 2014					
DB	226 GGAAGAAATTCAGCTCTAAGACTGGAGCTTACACATCAATCAATCAGCAGCTAA 168					
LOCUS	RESULT 15					
DEFINITION	B48260 607 bp DNA linear GSS 08-APR-1999					
ACCESSION	B48260					
VERSION	B48260.1 GI:2600497					
KEYWORDS	GSS.					
SOURCE	human.					
ORGANISM	Homo sapiens					
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.					
AUTHORS	Adams, M.D., Rounsley, S.D., Field, C.E., Baas, S., Linher, R., Golden, K., Berry, K., Granger, D., Sun, E., Wille, C., de Jong, P. and Venter, J.C.					
TITLE	Use of BAC End Sequences for Sequence-Ready Map Building					
JOURNAL	Unpublished (1997)					
COMMENT	Contact: Mark Adams					

Email: c9apbs-remail.nih.gov
 CDNA Library Preparation: David B. Krizman, Ph.D.
 DNA Library Arrayed by: I.M.A.G.E. Consortium, LNL
 DNA Sequencing by: Washington University Genome Sequencing Center
 found through the I.M.A.G.E. Consortium information can be
 www-bio.llnl.gov/bbrp/image/image.html
 Seq primer: -400P from GIBCO.

FEATURES

Source

Location/Qualifiers
 1. 199
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2052270"
 /clone_1lb="NCI CGAP Lu26"
 /tissue_type="invasive adenocarcinoma"
 /dev_stage="adult"
 /lab_host="DH10B"
 /note="Organ: Lung; Vector: pAMP1; mRNA made from lung
 adenocarcinoma tissue, CDNA made by oligo-dT priming.
 directionally cloned. Size-selected on agarose gel,
 average insert size 500 bp. Primary library,
 non-amplified."

BASE COUNT

93 a 38 c 40 g 28 t

Query Match

Best Local Similarity 1.7%; Score 35; DB 10; Length 199;
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db

2006 GCCAGCTAAAAA 2040
 111 GCCAGCTAAAAA 145

RESULT 40

AI344938

LOCUS

AI344938

DEFINITION

224 bp mRNA linear EST 30-DEC-1998
 cb01a04.x1 NCI CGAP Lu26 Homo sapiens CDNA clone IMAGE:2052270 3',
 mRNA sequence.

ACCESSION

AI344938
 AI344928.1 GI:4082134

KEYWORDS

EST.

SOURCE

human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 224)
 NCI CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)

JOURNAL

Contact: Robert Strausberg, Ph.D.

REFERENCE

Email: c9apbs-remail.nih.gov

AUTHORS

CDNA Library Preparation: David B. Krizman, Ph.D.

TITLE

DNA Sequencing by: Washington University Genome Sequencing Center

COMMENT

Clone distribution: NCI CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
 www-bio.llnl.gov/bbrp/image/image.html
 Seq primer: -400P from GIBCO.

FEATURES

Location/Qualifiers

1. 224
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2052270"
 /clone_1lb="NCI CGAP Lu26"
 /tissue_type="invasive adenocarcinoma"
 /dev_stage="adult"
 /lab_host="DH10B"
 /note="Organ: Lung; Vector: pAMP1; mRNA made from lung
 adenocarcinoma tissue, CDNA made by oligo-dT priming.
 directionally cloned. Size-selected on agarose gel,
 average insert size 500 bp. Primary library,
 non-amplified."

BASE COUNT 119 a 40 c 36 g 29 t
 ORIGIN

Query Match 1.7%; Score 35; DB 9; Length 224;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2006 GCCAGCTAAAAA 2040
 128 GCCAGCTAAAAA 162

RESULT 41

AI336592

LOCUS

AI336592

DEFINITION

232 bp mRNA linear EST 16-FEB-1999
 ta94d12.x1 NCI CGAP Lu26 Homo sapiens CDNA clone IMAGE:2051735 3',
 mRNA sequence.

ACCESSION

AI336592
 AI336592.1 GI:4073519

KEYWORDS

EST.

SOURCE

human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 232)
 NCI CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)

JOURNAL

Contact: Robert Strausberg, Ph.D.

REFERENCE

Email: c9apbs-remail.nih.gov

AUTHORS

CDNA Library Preparation: David B. Krizman, Ph.D.

TITLE

DNA Sequencing by: Washington University Genome Sequencing Center

COMMENT

Clone distribution: NCI CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
 www-bio.llnl.gov/bbrp/image/image.html
 Insert Length: 302 Std Error: 0.00
 Seq primer: -400P from GIBCO
 High quality sequence stop: 225.

FEATURES

Location/Qualifiers

1. 232
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:2051735"
 /clone_1lb="NCI CGAP Lu26"
 /tissue_type="invasive adenocarcinoma"
 /dev_stage="adult"
 /lab_host="DH10B"
 /note="Organ: Lung; Vector: pAMP1; mRNA made from lung
 adenocarcinoma tissue, CDNA made by oligo-dT priming.
 directionally cloned. Size-selected on agarose gel,
 average insert size 500 bp. Primary library,
 non-amplified."

BASE COUNT

119 a 44 c 40 g 29 t

ORIGIN

Query Match

1.7%; Score 35; DB 9; Length 232;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db

2006 GCCAGCTAAAAA 2040

LOCUS

AI344933

DEFINITION

cb01a11.x1 NCI CGAP Lu26 Homo sapiens CDNA clone IMAGE:2052284 3',
 mRNA sequence.

ACCESSION

AI344933

RESULT 42

AI344933

LOCUS

AI344933

DEFINITION

239 bp mRNA linear EST 16-FEB-1999

ACCESSION

AI344933

Int. Summary

```

VERSION AI344933.1 GI:4082139
KEYWORDS EST.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 239)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cga@bbs-remail.nih.gov
CDNA Library Preparation: David B. Krizman, Ph.D.
DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/dbp/image/image.html
Insert Length: 291 Std Error: 0.00
Seq primer: -400P from Gibco.

FEATURES
source
1. 239
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2052284"
/clone_1lb="NCI-CGAP_Lu26"
/tissue_type="invasive adenocarcinoma"
/dev_stage="adult"
/lab_host="DH10B"
/note="Organ: Lung; Vector: pAMP1; mRNA made from lung
adenocarcinoma tissue, cDNA made by oligo-dT priming.
directionally cloned. Size selected on agarose gel,
average insert size 500 bp. Primary library,
non-amplified."
BASE COUNT 119 a 48 c 40 g 32 t
ORIGIN
Query Match 1.7% Score 35; DB 9; Length 239;
Best Local Similarity 100.00; Pred. No. 27;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2006 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 2040
Db 146 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 180

RESULT 43
LOCUS AI344936 239 bp mRNA linear EST 30-DEC-1998
DEFINITION CB01B03.x1 NCI-CGAP_Lu26 Homo sapiens cDNA clone IMAGE:2052269 3',
mRNA sequence.
ACCESSION AI344936
VERSION AI344936.1 GI:4082142
KEYWORDS EST.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 239)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cga@bbs-remail.nih.gov
CDNA Library Preparation: David B. Krizman, Ph.D.
DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/dbp/image/image.html
Seq primer: -400P from Gibco.

```

```

FEATURES
source
1. 239
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2052269"
/clone_1lb="NCI-CGAP_Lu26"
/tissue_type="invasive adenocarcinoma"
/dev_stage="adult"
/lab_host="DH10B"
/note="Organ: Lung; Vector: pAMP1; mRNA made from lung
adenocarcinoma tissue, cDNA made by oligo-dT priming.
directionally cloned. Size selected on agarose gel,
average insert size 500 bp. Primary library,
non-amplified."
BASE COUNT 119 a 48 c 40 g 32 t
ORIGIN
Query Match 1.7% Score 35; DB 9; Length 239;
Best Local Similarity 100.00; Pred. No. 27;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2006 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 2040
Db 146 GCCAGCTAAAAAAAAAAAAAAAAAAAAA 180

RESULT 44
LOCUS AI335449 250 bp mRNA linear EST 29-DEC-1998
DEFINITION CB79F03.x1 NCI-CGAP_Lu26 Homo sapiens cDNA clone IMAGE:2060573 3',
mRNA sequence.
ACCESSION AI335449
VERSION AI335449.1 GI:4072376
KEYWORDS EST.
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 250)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap/
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cga@bbs-remail.nih.gov
CDNA Library Preparation: David B. Krizman, Ph.D.
DNA Sequencing by: I.M.A.G.E. Consortium, LLNL
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/dbp/image/image.html
Seq primer: -400P from Gibco.
High quality sequence stop: 240.

FEATURES
source
1. 250
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2060573"
/clone_1lb="NCI-CGAP_Lu26"
/tissue_type="invasive adenocarcinoma"
/dev_stage="adult"
/lab_host="DH10B"
/note="Organ: Lung; Vector: pAMP1; mRNA made from lung
adenocarcinoma tissue, cDNA made by oligo-dT priming.
directionally cloned. Size selected on agarose gel,
average insert size 500 bp. Primary library,
non-amplified."
BASE COUNT 136 a 43 c 41 g 30 t
ORIGIN
Query Match 1.7% Score 35; DB 9; Length 250;
Best Local Similarity 100.00; Pred. No. 26;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

9. Int Summary